Indoco Remedies promoters acquire 38,930 shares in open market

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • Promoters acquired 38,930 equity shares in the open market on September 8 and 9, 2026
  • Total promoter holding rose to 67,42,542 shares, or 7.30% of the voting capital
  • Aruna Suresh Kare entered the register with 14,526 shares; others increased holdings modestly
  • No shares are encumbered by pledge or lien within the promoter group
  • Disclosure filed under Regulation 29(2) of SEBI (SA) Regulations, 2011
powered bylight_fuzz_icon
50559212

*this image is generated using AI for illustrative purposes only.

Promoters of Indoco Remedies acquired 38,930 equity shares in the open market on September 8 and 9, 2026. The purchase brings the promoter group’s total holding to 67,42,542 shares, representing 7.30% of the company’s total voting capital.

The acquisition was made by Aditi M. Panandikar, Madhura Suresh Kare, Suresh G. Kare, and Aruna Suresh Kare, who are persons acting in concert. The transaction was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Shareholding Breakdown

Before the acquisition, the promoter group held 67,03,612 shares, accounting for 7.26% of the total share capital. Following the open market purchases, the individual holdings are as follows:

Promoter Shares Held Before Shares Acquired Shares Held After % Holding After
Aditi M. Panandikar 29,24,158 4,970 29,29,128 3.17%
Madhura Suresh Kare 24,86,513 4,900 24,91,413 2.70%
Suresh G. Kare 12,92,941 14,534 13,07,475 1.42%
Aruna Suresh Kare 0 14,526 14,526 0.02%
Total 67,03,612 38,930 67,42,542 7.30%

Aruna Suresh Kare, who previously held no shares, now holds 14,526 shares following this acquisition. The group’s total equity share capital remains at ₹18,46,07,210, divided into 9,23,03,605 equity shares of ₹2 each.

No Encumbrances Reported

The disclosure confirms that there are no shares encumbered by pledge, lien, or non-disposal undertakings within the promoter group. Additionally, there are no warrants or convertible securities held by the acquirers that would entitle them to receive further voting rights.

What the Numbers Show

The acquisition represents a marginal increase of 0.04 percentage points in the promoter group’s stake. Notably, Aruna Suresh Kare entered the shareholder register with a fresh holding of 14,526 shares, while existing holders Aditi M. Panandikar and Madhura Suresh Kare increased their stakes modestly. The absence of any encumbrances suggests a clean balance sheet regarding promoter holdings.

Historical Stock Returns for Indoco Remedies

1 Day5 Days1 Month6 Months1 Year5 Years
+3.23%-12.90%+7.54%+22.63%-13.83%-48.43%

How might the entry of Aruna Suresh Kare as a new promoter shareholder influence future corporate governance or succession planning at Indoco Remedies?

Given the clean status of promoter holdings with no encumbrances, could this signal potential for future equity-linked financing or dividend payouts?

Will this modest increase in promoter stake lead to any short-term volatility or sentiment shift in Indoco Remedies' stock price among retail investors?

Indoco Remedies Goa Plant II receives seven USFDA observations

scanx
Reviewed by
Shriram SScanX News Team
Key Highlights
  • Indoco Remedies' Goa Plant II received seven observations from the USFDA
  • The observations were issued in Form 483 following a regulatory inspection
  • The facility is identified as the sterile manufacturing unit
  • The company will submit a comprehensive response within the stipulated timeframe
powered bylight_fuzz_icon
50142246

*this image is generated using AI for illustrative purposes only.

Indoco Remedies Goa Plant II has received seven observations from the USFDA following an inspection of the facility. The company has stated it will provide a detailed response to the regulatory body soon.

Regulatory inspection outcome

The USFDA inspection of Indoco Remedies' Goa Plant II concluded with the issuance of seven observations. Such observations, typically documented on a Form 483, represent areas where the inspecting agency noted concerns or deficiencies at the inspected facility.

Indoco Remedies has acknowledged the observations and confirmed that a detailed response addressing each point will be submitted to the USFDA. The company did not specify a timeline for the submission of its response.

Key details

Parameter Details
Facility inspected Goa Plant II
Regulatory authority USFDA
Number of observations 7
Company response Detailed response to be submitted soon

Historical Stock Returns for Indoco Remedies

1 Day5 Days1 Month6 Months1 Year5 Years
+3.23%-12.90%+7.54%+22.63%-13.83%-48.43%

How might these seven USFDA observations impact Indoco Remedies' ability to secure new approvals or maintain existing product registrations in the US market?

What is the historical likelihood of a Form 483 leading to a Warning Letter or Import Alert for pharmaceutical manufacturers with similar observation counts?

Could this regulatory scrutiny affect investor sentiment and the stock price of Indoco Remedies in the short to medium term?

More News on Indoco Remedies

1 Year Returns:-13.83%